GPC Biotech announces issuance of United States patent for detecting diseased cells.
The technology utilizes libraries of short antisense fragments of RNA to inhibit the function of individual genes and selects for those genes whose inhibition in the diseased cells provide the desired therapeutic effect (e.g. the induction of apoptosis (programmed cell death) in tumor cells, but not in normal cells).
"This patent further strengthens GPC Biotech's already strong patent position. Our integrated technology platform allows us to address the great need in the biopharmaceutical industry of generating high quality validated targets. We have already started commercializing this technology on a non-exclusive basis and plan to further partner it in pharmaceutical or biotech alliances," commented Jeno Gyuris, Ph.D., Vice President, Molecular Technologies of GPC Biotech.
GPC Biotech is a genomics- and proteomics-driven drug discovery company focused on applying a number of proprietary genomic, proteomic and drug discovery technologies to accelerate the identification and validation of novel drug targets for development of mechanism-based drugs in oncology, infectious diseases and immunology. GPC Biotech has leading cell cycle expertise and a broad intellectual property position. Drug discovery alliance partners include: the ALTANA AG pharmaceuticals group Byk Gulden, Aventis Pharma, Boehringer Ingelheim International, Cell Genesys and MorphoSys.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Potential for drug discovery|
|Comment:||GPC Biotech announces issuance of United States patent for detecting diseased cells.(Potential for drug discovery)|
|Publication:||BIOTECH Patent News|
|Article Type:||Brief Article|
|Date:||Mar 1, 2002|
|Previous Article:||Viragen granted interferon patent.|
|Next Article:||U.S. Genomics awarded pioneering patent.|